 |
|
|
|
March 2008 Cover
|
|
For the first time in nearly a decade, a new drug from the NNRTI class (non-nucleoside reverse transcriptase inhibitor) has been approved in the United States: On January 18,
Intelence (TMC125, etravirine) joined Sustiva (efavirenz, Stocrin), Viramune (nevirapine), and the little-used Rescriptor (delavirdine) on the NNRTI roster.
Intelence is the first approved NNRTI that appears to work against HIV already resistant to other NNRTIs, which may make it an option for people who can no longer use Sustiva
or Viramune.
from TheBody.com
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
